California firm takes cannabinoid research personally

by Invesbrain Tuesday, July 18, 2017
Print This Article

California firm looks to Israel for personalized cannabinoid approach

The news magazine ISRAEL21c reports a U.S. biopharma company is teaming up with an Israeli counterpart to forward the use of cannabinoids in the field of personalized medicine.

California-based CURE Pharmaceutical recently signed a memorandum of understanding with Therapix Biosciences of Tel Aviv. The “research collaboration” will be done in conjunction with the eight hospitals and medical centres of Israel’s Assuta Medical Centers.

Therapix’s lead compound THX-TS01 is currently in phase 2 clinical trials to treat Tourette’s syndrome. It hopes to begin a Phase 1 clinical trial for another compound, THX-ULD01, for the treatment of mild cognitive impairment.

Both compounds employ an “FDA-approved synthetic THC.”

Therapix is also developing new cannabinoid delivery technologies including nasal and sublingual (under the tongue) methods.

(READ MORE)

CMAJ commentary argues for two-stream cannabis system

Arguing ‘recreational cannabis and cannabinoid-based drugs (including medical cannabis) are not equivalent,’ the authors of a commentary in the Canadian Medical Association Journal say Canada should continue with a separate medical cannabis stream after legalization.

In a report by EurekAlert!, Elizabeth Cairns and Dr. Melanie Kelly of Dalhousie University’s Department of Pharmacology, write that “(without) a program that supports medical use, patients may lose access to treatments that the Federal Court of Canada has deemed appropriate, which fosters safe and appropriate use."

The Task Force on Cannabis Legalization and Regulation also recommended a two-streamed system.
According to the EurekAlert! report, “the authors suggest that a medical stream for cannabis and cannabinoids would reduce risk to patients, provide incentives for research into the therapeutic effects of cannabinoids, and provide educational resources for health care practitioners on the latest advances in cannabinoid research.”

(READ MORE)

U.S.-German-Israeli deal links cancer diagnostics with cannabinoids

MMJ Reporter writes an American cannabinoid firm with an R&D foothold in Israel is teaming up with a German “world pioneer in cancer diagnostics.”

Cannabics Pharmaceuticals Inc. recently agreed to become “the exclusive international provider unit” of SIMFO GmbH’s Circulating Tumour Cell (CTC) diagnostics to people suffering with cancer and being treated with CBDs.

SIMFO previously initiated preclinical trials into CBDs and drug development with Cannabics’ cannabinoid formulations.

Cannabics’ R&D facility is “concentrated” in Israel.

(READ MORE)

Data on CBD analogue to be presented at neuroscience meeting

Stockhouse reports Califonia-based NEMUS Bioscience is set to present research on its CBD analogue at the Annual Meeting of the Society of Neuroscience this November.

The data, compiled by NEMUS’ R&D partner the University of Mississippi “will show the superiority of the NEMUS proprietary analogue of CBD, NB2222, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator.”

The firm will also present data on the anti-addictive potential of NB2222.

"We have been able to demonstrate that NB2222 was able to deliver analgesia comparable to morphine, which has been implicated in the current global opioid abuse epidemic. The research team then moved to the next step using a validated animal model of addiction to opioids to assess the anti-abuse potential of NB2222 as a therapeutic. We look forward to presenting the data this fall," said Dr. Kenneth Sufka, research professor with the National Center for Natural Products Research at UM.

(READ MORE)

“E” vs “SG” in ethical investing: how sustainable is mollification-by-cherrypicking

In the great game of whack-a-mole that is capital raising in Canada’s oil patch, it must be frustrating, for those whose full-time job when there isn’t a global pandemic is whacking the moles of ESG criteria on which they feel their companies may be vulnerable to criticism a...

4Front Ventures has an upside of 245%, says Beacon Securities

Having right-sized the ship, 4Front Ventures (4Front Ventures Stock Quote, Chart, News CSE:FFNT) is primed for a strong H2 2020, according to Beacon Securities analyst Doug Cooper, who reviewed the cannabis company’s latest quarterly results in an update to clients on Tuesday....

Fire & Flower is our Top Pick in cannabis, says AltaCorp

AltaCorp Capital analyst David Kideckel is staying with Fire & Flower (Fire & Flower Stock Quote, Chart, News TSX:FAF) as his “Top Pick” in the cannabis space after the cannabis retailer’s recent quarterly earnings. In an update to clients Tuesday, Kideckel said FAF’s Hi...

Flower One is a beaten down pot stock worth owning: Mackie Research

Mackie Research analyst Greg McLeish likes the look of US cannabis play Flower One (Flower One Stock Quote, Chart, News CSE:FONE) after the company latest quarterly results. McLeish reviewed FONE’s fourth quarter 2019 and year-end results in an update to clients on Wednesday a...

The new reality: hoarding or avoiding using cash because of Covid- 19 and the relevance of Quantitative Easing

Keynes wrote at length about the increased attachment to cash which he called increased liquidity preference in a time of crisis which leads to a rise in the rate of interest as there are limits to the amount of cash in circulation. Keynes puts it as follows in his Quarterly Jou...

The political economy of Covid 19 in the early 21st century

The covid pandemic has had already a very significant impact beginning with the tragic death of over 100,000 people in North America alone. 6545 in Canada, 7633 in Mexico and a staggering 99,459 in the United States. World wide the total number of deaths is 347,873.As the New Yo...

Fiscal Conservatives renew their attack on government spending complaining that Covid -19 counter measures excessively increase deficits and government share of the economy

The American largely Republican Party dominated fiscal conservative lobby of policy advisors, academics and commentators have begun once again to try to undermine the very sensible congressional policy spending and investment plans which Congress has passed and which the House h...

What are Canada’s de minimis thresholds for courier shipments?

When it was announced that Canada, the United States and Mexico had reached an agreement to amend the North American Free Trade Agreement (“NAFTA”), one of the important changes was an increase to the de minimis threshold, which is the monetary value of courier shipments tha...

March 27, 2020

So the markets did not have a nice time today: Canada’s main stock market resumed its slide after a three-day winning run as investors grew more nervous about the spread of the coronavirus pandemic and the Bank of Canada slashed interest rates to nearly zero. The Toronto ...

March 30, 2020

Oil action is in the news today: Energy stocks led Canada’s main stock index higher on Monday, despite a plunge in crude prices as the market waits for news of support from Ottawa for the oil and gas industry. The Toronto Stock Exchange’s S&P/TSX composite index was unof...